{"title": "Nuvaxovid\u2122 de Novavax recibe la opini\u00f3n positiva del CHMP para la autorizaci\u00f3n de comercializaci\u00f3n completa", "author": "Novavax; Inc", "url": "https://www.prnewswire.com/news-releases/nuvaxovid-de-novavax-recibe-la-opinion-positiva-del-chmp-para-la-autorizacion-de-comercializacion-completa-301836713.html", "hostname": "prnewswire.com", "description": "/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), una compa\u00f1\u00eda global que promueve vacunas basadas en prote\u00ednas con su novedoso adyuvante Matrix-M\u2122, anunci\u00f3 hoy...", "sitename": "PR Newswire", "date": "2023-05-29", "id": null, "license": null, "body": null, "comments": "Share this article", "commentsbody": null, "raw_text": null, "text": "Nuvaxovid\u2122 de Novavax recibe la opini\u00f3n positiva del CHMP para la autorizaci\u00f3n de comercializaci\u00f3n completa\n[Novavax, Inc.](/news/novavax%2C-inc./)\n29 May, 2023, 14:38 ET\n[]\n- Nuvaxovid\u2122 de Novavax recibe la opini\u00f3n positiva del CHMP para la autorizaci\u00f3n de comercializaci\u00f3n completa para la prevenci\u00f3n de la COVID en la UE\nGAITHERSBURG, Md., 29 de mayo de 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)), una compa\u00f1\u00eda global que promueve vacunas basadas en prote\u00ednas con su novedoso adyuvante Matrix-M\u2122, anunci\u00f3 hoy que Nuvaxovid\u2122 (NVX-CoV2373) ha sido recomendado para la Autorizaci\u00f3n de Comercializaci\u00f3n (MA) completa para su uso como una serie primaria en personas mayores de 12 a\u00f1os y como refuerzo en personas mayores de 18 a\u00f1os para la prevenci\u00f3n de la COVID-19 en la Uni\u00f3n Europea (UE) tras una opini\u00f3n positiva emitida por el Comit\u00e9 de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos. La Comisi\u00f3n Europea revisar\u00e1 la recomendaci\u00f3n del CHMP y se espera que tome una decisi\u00f3n final sobre la EM.\n\"La opini\u00f3n positiva del CHMP para la autorizaci\u00f3n de comercializaci\u00f3n completa de nuestra vacuna de la COVID nos acerca un paso m\u00e1s a la autorizaci\u00f3n completa y proporcionar\u00e1 una v\u00eda de aprobaci\u00f3n para una vacuna actualizada a tiempo para el oto\u00f1o\", explic\u00f3 John C. Jacobs, presidente y consejero delegado de Novavax.\nNovavax ha demostrado la eficacia y seguridad de Nuvaxovid como serie primaria, y la inmunogenicidad y seguridad de la vacuna como refuerzo en personas de 12 a\u00f1os o m\u00e1s en el ensayo de fase 3 PREVENT-19, ensayos de fase 2 y en pruebas del mundo real.\nLa vacuna de la COVID de Novavax est\u00e1 autorizada para su uso en m\u00e1s de 40 mercados en todo el mundo. En la UE, Nuvaxovid ha sido autorizado condicionalmente como serie primaria de dos dosis en\n[adultos](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=3534653529&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D3454893251%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%26a%3Dadults&a=adultos) y [adolescentes](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2202844626&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2243608504%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-07-05-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Conditionally-Authorized-in-the-European-Union-for-Adolescents-Aged-12-Through-17%26a%3Dadolescents%252C&a=adolescentes), y como [dosis de refuerzo en adultos](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2627674766&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2102273684%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-09-12-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Granted-Expanded-Conditional-Marketing-Authorization-in-the-European-Union-for-Use-as-a-Booster-for-Adults-Aged-18-&a=dosis+de+refuerzo+en+adultos).\nNombre comercial en Estados Unidos\nEl nombre comercial Nuvaxovid\u2122 a\u00fan no ha sido aprobado por la Administraci\u00f3n de F\u00e1rmacos y Alimentos de Estados Unidos (FDA).\nUso de la vacuna Novavax COVID-19, con adyuvante en Estados Unidos\nLa vacuna Novavax COVID-19, vacuna con adyuvante no ha sido aprobada ni autorizada por la FDA de los Estados Unidos, pero ha sido autorizada para uso de emergencia por la FDA, bajo una Autorizaci\u00f3n de uso de emergencia (EUA) para prevenir la enfermedad por coronavirus 2019 (COVID-19) como una serie primaria en individuos de 12 a\u00f1os de edad y mayores. La vacuna Novavax COVID-19, vacuna adyuvada tambi\u00e9n est\u00e1 autorizada para proporcionar una primera dosis de refuerzo al menos 6 meses despu\u00e9s de completar la vacunaci\u00f3n primaria con una vacuna de la COVID-19 autorizada o aprobada a personas de 18 a\u00f1os de edad y mayores para quienes una vacuna autorizada por la FDA. La vacuna de refuerzo contra la COVID-19 bivalente de ARNm no es accesible o cl\u00ednicamente apropiada, y para las personas mayores de 18 a\u00f1os que eligen recibir la vacuna contra la COVID-19 de Novavax, con adyuvante porque de otro modo no recibir\u00edan una dosis de refuerzo de una vacuna contra la COVID-19.\nEl uso de emergencia de este producto solo est\u00e1 autorizado mientras dure la declaraci\u00f3n de que existen circunstancias que justifican la autorizaci\u00f3n del uso de emergencia del producto m\u00e9dico seg\u00fan la Secci\u00f3n 564(b)(1) de la Ley FD&C, a menos que la declaraci\u00f3n finalice o la autorizaci\u00f3n se revoque antes.\nUso autorizado\nLa vacuna Novavax COVID-19, adyuvada est\u00e1 autorizada para su uso bajo una autorizaci\u00f3n de uso de emergencia (EUA) para proporcionar una serie primaria de dos dosis para la inmunizaci\u00f3n activa para prevenir la enfermedad por coronavirus 2019 (COVID-19) causada por el s\u00edndrome respiratorio agudo severo coronavirus 2 ( SARS-CoV-2) en personas mayores de 12 a\u00f1os. La vacuna Novavax COVID-19, vacuna adyuvada tambi\u00e9n est\u00e1 autorizada para proporcionar una primera dosis de refuerzo al menos 6 meses despu\u00e9s de completar la vacunaci\u00f3n primaria con una vacuna COVID-19 autorizada o aprobada a personas de 18 a\u00f1os de edad y mayores para quienes una vacuna autorizada por la FDA. La vacuna de refuerzo contra la COVID-19 bivalente de ARNm no es accesible o cl\u00ednicamente apropiada, y para las personas mayores de 18 a\u00f1os que eligen recibir la vacuna contra la COVID-19 de Novavax, con adyuvante porque de otro modo no recibir\u00edan una dosis de refuerzo de una vacuna contra la COVID-19.\nINFORMACI\u00d3N DE SEGURIDAD IMPORTANTE\nContraindicaciones\nNo administre la vacuna Novavax COVID-19, con adyuvante a personas con antecedentes conocidos de una reacci\u00f3n al\u00e9rgica grave (p. ej., anafilaxia) a cualquier componente de la vacuna Novavax COVID-19, con adyuvante.\nNo administre la vacuna Novavax COVID-19, con adyuvante a personas con antecedentes conocidos de una reacci\u00f3n al\u00e9rgica grave (p. ej., anafilaxia) a cualquier componente de la vacuna Novavax COVID-19, con adyuvante.\nAdvertencias y precauciones\nManejo de reacciones al\u00e9rgicas agudas: el tratamiento m\u00e9dico adecuado para manejar las reacciones al\u00e9rgicas inmediatas debe estar disponible de inmediato en caso de que ocurra una reacci\u00f3n anafil\u00e1ctica aguda despu\u00e9s de la administraci\u00f3n de la vacuna Novavax COVID-19, adyuvada. Supervise los receptores de la vacuna Novavax COVID-19 con adyuvante para detectar la aparici\u00f3n de reacciones adversas inmediatas de acuerdo con las pautas de los\n[Centros para el Control y la Prevenci\u00f3n de Enfermedades (CDC).](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=4132480547&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D313628848%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3781243-1%2526h%253D2738452371%2526u%253Dhttps%25253A%25252F%25252Fwww.cdc.gov%25252Fvaccines%25252Fcovid-19%25252Fclinical-considerations%25252Fmanaging-anap&a=Centros+para+el+Control+y+la+Prevenci%C3%B3n+de+Enfermedades+(CDC).)\nMiocarditis y pericarditis: los datos de los ensayos cl\u00ednicos proporcionan evidencia de un mayor riesgo de miocarditis y pericarditis despu\u00e9s de la administraci\u00f3n de la vacuna Novavax COVID-19, adyuvada (consulte la informaci\u00f3n de prescripci\u00f3n completa de la EUA). El CDC ha publicado consideraciones relacionadas con la miocarditis y la pericarditis despu\u00e9s de la vacunaci\u00f3n, incluida la vacunaci\u00f3n de personas con antecedentes de miocarditis o pericarditis (\n[https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#myocarditis-pericarditis](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=595147852&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2397580223%26u%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fvaccines%252Fcovid-19%252Fclinical-considerations%252Finterim-considerations-us.html%2523myocarditis-pericarditis%26a%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fvaccines%252Fcovid-19%252Fclinical-considerations%252Finterim-considerations-us.html%2523myocarditis-pericarditis&a=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Fclinical-considerations%2Finterim-considerations-us.html%23myocarditis-pericarditis)).\nS\u00edncope (desmayo): puede ocurrir en asociaci\u00f3n con la administraci\u00f3n de vacunas inyectables. Deben existir procedimientos para evitar lesiones por desmayo.\nInmunocompetencia alterada: las personas inmunodeprimidas, incluidas las personas que reciben terapia inmunosupresora, pueden tener una respuesta inmunitaria disminuida a la vacuna Novavax COVID-19, adyuvada.\nLimitaciones de la eficacia de la vacuna: es posible que la vacuna Novavax COVID-19 con adyuvante no proteja a todos los receptores de la vacuna.\nReacciones adversas\nLas reacciones adversas notificadas en ensayos cl\u00ednicos despu\u00e9s de la administraci\u00f3n de la vacuna Novavax COVID-19 con adyuvante incluyen dolor/sensibilidad en el lugar de la inyecci\u00f3n, fatiga/malestar general, dolor muscular, dolor de cabeza, dolor en las articulaciones, n\u00e1useas/v\u00f3mitos, enrojecimiento en el lugar de la inyecci\u00f3n, hinchaz\u00f3n en el lugar de la inyecci\u00f3n, fiebre, escalofr\u00edos, prurito en el lugar de la inyecci\u00f3n, reacciones de hipersensibilidad, reacciones relacionadas con linfadenopat\u00eda, miocarditis y pericarditis.\nSe han informado miocarditis, pericarditis, anafilaxia, parestesia e hipoestesia despu\u00e9s de la administraci\u00f3n de la vacuna Novavax COVID-19, con adyuvante fuera de los ensayos cl\u00ednicos.\nLas reacciones adversas adicionales, algunas de las cuales pueden ser graves, pueden manifestarse con el uso m\u00e1s generalizado de la vacuna Novavax COVID-19, adyuvada.\nNotificaci\u00f3n de eventos adversos y errores de administraci\u00f3n de vacunas\nEl proveedor de vacunas inscrito en el Programa federal de vacunaci\u00f3n contra la COVID-19 es responsable de informar obligatoriamente lo siguiente al Sistema de notificaci\u00f3n de eventos adversos de vacunas (VAERS):\n- errores en la administraci\u00f3n de vacunas, est\u00e9n o no asociados con un evento adverso,\n- eventos adversos graves (independientemente de la atribuci\u00f3n a la vacunaci\u00f3n),\n- casos de miocarditis,\n- casos de pericarditis,\n- casos de S\u00edndrome Inflamatorio Multisist\u00e9mico (MIS), en adultos y ni\u00f1os, y\n- casos de la COVID-19 que resultan en hospitalizaci\u00f3n o muerte.\nComplete y env\u00ede informes a VAERS en l\u00ednea: para obtener m\u00e1s ayuda con la presentaci\u00f3n de informes a VAERS, llame al 1-800-822-7967. Los informes deben incluir las palabras \"Vacuna Novavax COVID-19, EUA con adyuvante\" en la secci\u00f3n de descripci\u00f3n del informe.\nEn la medida de lo posible, informe de los eventos adversos a Novavax, Inc. utilizando la siguiente informaci\u00f3n de contacto o proporcionando una copia del formulario VAERS a Novavax, Inc. Sitio web:\n[www.NovavaxMedInfo.com](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=729331448&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D3497786127%26u%3Dhttp%253A%252F%252Fwww.novavaxmedinfo.com%252F%26a%3Dwww.NovavaxMedInfo.com&a=www.NovavaxMedInfo.com), N\u00famero de fax: 1-888-988-8809, N\u00famero de tel\u00e9fono: 1-844-NOVAVAX (1-844-668-2829).\nHaga clic para ver la\n[vacuna contra el COVID-19 de Novavax, la hoja informativa con adyuvante para proveedores de atenci\u00f3n m\u00e9dica que administran la vacuna (proveedores de vacunas) y la informaci\u00f3n de prescripci\u00f3n completa de la EUA](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2447828334&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D563384075%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3781243-1%2526h%253D1136151556%2526u%253Dhttps%25253A%25252F%25252Fwww.fda.gov%25252Fmedia%25252F159897%25252Fdownload%2526a%253DNovavax%252BCOVID-19%252BVaccine%2525&a=vacuna+contra+el+COVID-19+de+Novavax%2C+la+hoja+informativa+con+adyuvante+para+proveedores+de+atenci%C3%B3n+m%C3%A9dica+que+administran+la+vacuna+(proveedores+de+vacunas)+y+la+informaci%C3%B3n+de+prescripci%C3%B3n+completa+de+la+EUA).\nHaga clic para ver la\n[hoja informativa para beneficiarios y cuidadores](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=4223651868&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D1936408935%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3781243-1%2526h%253D170356972%2526u%253Dhttps%25253A%25252F%25252Fnovavax.widen.net%25252Fs%25252Fx5p5tqsdgw%25252Fus-eua-fact-sheet-recipients%2526a%253DFact%2525&a=hoja+informativa+para+beneficiarios+y+cuidadores).\nAcerca de Nuvaxovid\u2122 (NVX-CoV2373)\nNVX-CoV2373 es una vacuna a base de prote\u00ednas creada mediante la creaci\u00f3n de copias de la prote\u00edna de punta de superficie del SARS-CoV-2 que causa la COVID. Con la exclusiva tecnolog\u00eda de nanopart\u00edculas recombinantes de Novavax, la prote\u00edna espiga no infecciosa sirve como ant\u00edgeno que prepara al sistema inmunitario para reconocer el virus, mientras que el adyuvante Matrix-M de Novavax mejora y ampl\u00eda la respuesta inmunitaria. La vacuna se envasa como una formulaci\u00f3n l\u00edquida lista para usar y se almacena entre 2 \u00b0C y 8 \u00b0C, lo que permite el uso de los canales de cadena de fr\u00edo y suministro de vacunas existentes.\nAcerca del ensayo de fase 3 PREVENT-19\nLa subunidad de prote\u00edna de fusi\u00f3n PREVaccineEfficacyNovavaxTrial COVID-19 (PREVENT-19) fue un ensayo de fase 3 aleatorizado, controlado con placebo y ciego para el observador realizado en los Estados Unidos y M\u00e9xico para evaluar la eficacia y seguridad de NVX-CoV2373 como serie primaria y como refuerzo en adultos y adolescentes para prevenir la infecci\u00f3n por SARS-CoV-2. Como serie primaria, el criterio principal de valoraci\u00f3n fue la primera aparici\u00f3n de la COVID-19 sintom\u00e1tico (leve, moderado o grave) confirmado por reacci\u00f3n en cadena de la polimerasa (PCR) con aparici\u00f3n al menos siete d\u00edas despu\u00e9s de la segunda dosis en 29 960 participantes adultos mayores de 18 a\u00f1os al inicio del estudio sin violaciones del protocolo antes de la enfermedad. Un criterio de valoraci\u00f3n secundario fue la prevenci\u00f3n de la COVID-19 sintom\u00e1tica moderada o grave confirmada por PCR. Los resultados completos del ensayo se publicaron en el\n[New England Journal of Medicine](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=3673984913&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D1517842101%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3625115-1%2526h%253D371124133%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3440781-1%252526h%25253D467849857%252526u%25253Dhttps%2525253A%2525252F%2525252Fwww.nejm.org%2525252Fdoi%2525252Ffull%2525252F10.1056%2525252FNEJMoa2116185%2525253Fquery%2525253Dfeatured_home%252526a%25253DNew%25252BEngland%25252BJournal%25252Bof%25252BMedicine%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine).\nLa expansi\u00f3n pedi\u00e1trica del ensayo evalu\u00f3 a 2.247 adolescentes de 12 a 17 a\u00f1os en Estados Unidos. Los resultados de la expansi\u00f3n se anunciaron en\n[febrero de 2022](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2530463928&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D3487787302%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial%26a%3DFebruary%2B2022&a=febrero+de+2022). La expansi\u00f3n de refuerzo para adultos del ensayo evalu\u00f3 una sola dosis de refuerzo de la vacuna en participantes adultos aproximadamente seis meses despu\u00e9s de su serie de vacunaci\u00f3n primaria de dos dosis. Los resultados de la expansi\u00f3n se anunciaron en [octubre de 2022](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2732136443&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2988797656%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-10-12-Novavax-Prototype-COVID-19-Vaccine-Data-Support-Homologous-and-Heterologous-Boosting-and-Suggest-Benefit-Against-Variants%26a%3DOctober%2B2022&a=octubre+de+2022).\nAcerca del adyuvante Matrix-M\u2122\nCuando se agrega a las vacunas, el adyuvante Matrix-M basado en saponina patentado de Novavax mejora la respuesta del sistema inmunitario, haci\u00e9ndolo m\u00e1s fuerte, m\u00e1s amplio y m\u00e1s duradero. El adyuvante Matrix-M estimula la entrada de c\u00e9lulas presentadoras de ant\u00edgenos en el lugar de la inyecci\u00f3n y mejora la presentaci\u00f3n de ant\u00edgenos en los ganglios linf\u00e1ticos locales.\nAcerca de Novavax\nNovavax, Inc. (Nasdaq:\n[NVAX](#financial-modal)) promueve una mejor salud al descubrir, desarrollar y comercializar vacunas innovadoras para proteger contra enfermedades infecciosas graves. Novavax, una compa\u00f1\u00eda global con sede en Gaithersburg, Maryland, Estados Unidos, ofrece una plataforma de vacuna diferenciada que combina un enfoque de prote\u00edna recombinante, tecnolog\u00eda innovadora de nanopart\u00edculas y el adyuvante Matrix-M patentado de Novavax para mejorar la respuesta inmunitaria. Centrado en los desaf\u00edos de salud m\u00e1s urgentes del mundo, Novavax actualmente est\u00e1 evaluando vacunas para la COVID, influenza y la COVID e influenza combinados. Visite [novavax.com](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2467048701&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D1476516171%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3625115-1%2526h%253D372019113%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3460980-1%252526h%25253D3623927874%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3457869-1%25252526h%2525253D982408174%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3440781-1%2525252526h%252525253D3964594936%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3395501-1%252525252526h%25252525253D2463599076%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3392093-1%25252525252526h%2525252525253D203886192%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3387216-1%2525252525252526h%252525252525253D3917401194%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fc212.net%25252525252525252Fc%25252525252525252Flink%25252525252525252F%25252525252525253Ft%25252525252525253D0%252525252525252526l%25252525252525253Den%252525252525252526o%25252525252525253D3260461-1%252525252525252526h%25252525252525253D2897486098%252525252525252526u%25252525252525253Dhttp%2525252525252525253A%2525252525252525252F%2525252525252525252Fwww.novavax.com%2525252525252525252F%252525252525252526a%25252525252525253Dwww.novavax.com%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.&a=novavax.com) y\nDeclaraciones prospectivas\nDeclaraciones en este documento relacionadas con el futuro de Novavax, sus planes operativos y perspectivas, el desarrollo continuo de NVX-CoV2373, su estrategia regulatoria y v\u00edas de aprobaci\u00f3n en relaci\u00f3n con NVX-CoV2373 y sus vacunas de la COVID-19 basadas en variantes, el alcance, el momento y el resultado de futuras presentaciones y acciones regulatorias, autorizaciones en Europa y autorizaciones adicionales en todo el mundo de NVX-CoV2373 para su uso en adultos y adolescentes, y como refuerzo, la evoluci\u00f3n de la pandemia de la COVID-19, el impacto potencial y el alcance de Novavax y NVX-CoV2373 para abordar el acceso a la vacuna, la protecci\u00f3n de las poblaciones, la eficacia, el uso previsto de seguridad y la administraci\u00f3n esperada de NVX-CoV2373 son declaraciones prospectivas. Novavax advierte que estas declaraciones prospectivas est\u00e1n sujetas a numerosos riesgos e incertidumbres que podr\u00edan causar que los resultados reales difieran materialmente de los expresados o impl\u00edcitos en dichas declaraciones. Estos riesgos e incertidumbres incluyen, entre otros, desaf\u00edos para satisfacer, solo o junto con socios, varios requisitos de seguridad, eficacia y caracterizaci\u00f3n de productos, incluidos los relacionados con la calificaci\u00f3n del proceso y la validaci\u00f3n del ensayo, necesarios para satisfacer a las autoridades reguladoras aplicables; dificultad para obtener materias primas y suministros escasos; limitaciones de recursos, incluido el capital humano y la capacidad de fabricaci\u00f3n, sobre la capacidad de Novavax para seguir las v\u00edas regulatorias planificadas; desaf\u00edos imprevistos o retrasos en la realizaci\u00f3n de ensayos cl\u00ednicos; desaf\u00edos para cumplir con los requisitos contractuales en virtud de acuerdos con m\u00faltiples entidades comerciales, gubernamentales y de otro tipo; y aquellos otros factores de riesgo identificados en las secciones \"Factores de riesgo\" y \"Discusi\u00f3n y an\u00e1lisis de la administraci\u00f3n de la situaci\u00f3n financiera y los resultados de las operaciones\" del Informe anual de Novavax en el Formulario 10-K para el a\u00f1o finalizado el 31 de diciembre de 2022 y los Informes trimestrales posteriores en el Formulario 10-Q, tal como se present\u00f3 ante la Comisi\u00f3n de Bolsa y Valores (SEC). Advertimos a los inversores que no conf\u00eden demasiado en las declaraciones prospectivas contenidas en este comunicado de prensa. Le animamos a leer nuestras presentaciones ante la SEC, disponibles en\n[www.sec.gov](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=1427378382&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2482378409%26u%3Dhttps%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov) y [www.novavax.com](https://www.novavax.com), para una discusi\u00f3n de estos y otros riesgos e incertidumbres. Las declaraciones a futuro en este comunicado de prensa se refieren solo a la fecha de este documento, y no asumimos ninguna obligaci\u00f3n de actualizar o revisar ninguna de las declaraciones. Nuestro negocio est\u00e1 sujeto a riesgos e incertidumbres sustanciales, incluidos los mencionados anteriormente. Los inversores, los inversores potenciales y otros deben considerar cuidadosamente estos riesgos e incertidumbres.\nContactos:\nInversores\nErika Schultz\n240-268-2022\n[[email protected]](/cdn-cgi/l/email-protection#e38a91a38d8c958295829bcd808c8e)\nMedios\nAli Chartan\n240-720-7804\n[[email protected]](/cdn-cgi/l/email-protection#a9c4cccdc0c8e9c7c6dfc8dfc8d187cac6c4)\nLogo -\n[https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg](https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=3784787682&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2238742483%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg)\nSOURCE Novavax, Inc.", "language": null, "image": "https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg?p=facebook", "pagetype": "articles", "links": ["/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "https://portal.prnewswire.com/Login.aspx", "https://www.prnewswire.com/account/online-membership-form/", "https://gdpr.cision.com/", "https://portal.prnewswire.com/Login.aspx", "/", "/news-releases/", "/products/overview/", "/contact-us/", "#", "/news-releases/", "/news-releases/news-releases-list/", "/news-releases/all-public-company-news/", "/news-releases/english-releases/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/multimedia/multimedia-list/", "/news-releases/photos/photos-list/", "/news-releases/videos/videos-list/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/latest-news-topics/", "#", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/automotive-transportation-latest-news/aerospace-defense-list/", "/news-releases/automotive-transportation-latest-news/air-freight-list/", "/news-releases/automotive-transportation-latest-news/airlines-aviation-list/", "/news-releases/automotive-transportation-latest-news/automotive-list/", "/news-releases/automotive-transportation-latest-news/maritime-shipbuilding-list/", "/news-releases/automotive-transportation-latest-news/railroads-and-intermodal-transportation-list/", "/news-releases/automotive-transportation-latest-news/supply-chain-logistics-list/", "/news-releases/automotive-transportation-latest-news/transportation-trucking-railroad-list/", "/news-releases/automotive-transportation-latest-news/travel-list/", "/news-releases/automotive-transportation-latest-news/trucking-and-road-transportation-list/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/automotive-transportation-latest-news/automotive-transportation-latest-news-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/business-technology-latest-news/blockchain-list/", "/news-releases/business-technology-latest-news/broadcast-tech-list/", "/news-releases/business-technology-latest-news/computer-electronics-list/", "/news-releases/business-technology-latest-news/computer-hardware-list/", "/news-releases/business-technology-latest-news/computer-software-list/", "/news-releases/business-technology-latest-news/data-analytics-list/", "/news-releases/business-technology-latest-news/electronic-commerce-list/", "/news-releases/business-technology-latest-news/electronic-components-list/", "/news-releases/business-technology-latest-news/electronic-design-automation-list/", "/news-releases/business-technology-latest-news/financial-technology-list/", "/news-releases/business-technology-latest-news/high-tech-security-list/", "/news-releases/business-technology-latest-news/internet-technology-list/", "/news-releases/business-technology-latest-news/nanotechnology-list/", "/news-releases/business-technology-latest-news/networks-list/", "/news-releases/business-technology-latest-news/peripherals-list/", "/news-releases/business-technology-latest-news/semiconductors-list/", "/news-releases/business-technology-latest-news/", "/news-releases/business-technology-latest-news/business-technology-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/financial-services-latest-news/accounting-news-issues-list/", "/news-releases/financial-services-latest-news/acquisitions-mergers-and-takeovers-list/", "/news-releases/financial-services-latest-news/banking-financial-services-list/", "/news-releases/financial-services-latest-news/bankruptcy-list/", "/news-releases/financial-services-latest-news/bond-stock-ratings-list/", "/news-releases/financial-services-latest-news/conference-call-announcements-list/", "/news-releases/financial-services-latest-news/contracts-list/", "/news-releases/financial-services-latest-news/cryptocurrency-list/", "/news-releases/financial-services-latest-news/dividends-list/", "/news-releases/financial-services-latest-news/earnings-list/", "/news-releases/financial-services-latest-news/earnings-forecasts-projections-list/", "/news-releases/financial-services-latest-news/financing-agreements-list/", "/news-releases/financial-services-latest-news/insurance-list/", "/news-releases/financial-services-latest-news/investment-opinions-list/", "/news-releases/financial-services-latest-news/joint-ventures-list/", "/news-releases/financial-services-latest-news/mutual-funds-list/", "/news-releases/financial-services-latest-news/private-placement-list/", "/news-releases/financial-services-latest-news/real-estate-list/", "/news-releases/financial-services-latest-news/restructuring-recapitalization-list/", "/news-releases/financial-services-latest-news/sales-reports-list/", "/news-releases/financial-services-latest-news/shareholder-activism-list/", "/news-releases/financial-services-latest-news/shareholder-meetings-list/", "/news-releases/financial-services-latest-news/stock-offering-list/", "/news-releases/financial-services-latest-news/stock-split-list/", "/news-releases/financial-services-latest-news/venture-capital-list/", "/news-releases/financial-services-latest-news/", "/news-releases/financial-services-latest-news/financial-services-latest-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "/news-releases/general-business-latest-news/awards-list/", "/news-releases/general-business-latest-news/commercial-real-estate-list/", "/news-releases/general-business-latest-news/corporate-expansion-list/", "/news-releases/general-business-latest-news/earnings-list/", "/news-releases/general-business-latest-news/environmental-social-governance-list/", "/news-releases/general-business-latest-news/human-resource-workforce-management-list/", "/news-releases/general-business-latest-news/licensing-list/", "/news-releases/general-business-latest-news/new-products-services-list/", "/news-releases/general-business-latest-news/obituaries-list/", "/news-releases/general-business-latest-news/outsourcing-businesses-list/", "/news-releases/general-business-latest-news/overseas-real-estate-list/", "/news-releases/general-business-latest-news/personnel-announcements-list/", "/news-releases/general-business-latest-news/real-estate-transactions-list/", "/news-releases/general-business-latest-news/residential-real-estate-list/", "/news-releases/general-business-latest-news/small-business-services-list/", "/news-releases/general-business-latest-news/socially-responsible-investing-list/", "/news-releases/general-business-latest-news/surveys-polls-and-research-list/", "/news-releases/general-business-latest-news/trade-show-news-list/", "/news-releases/general-business-latest-news/", "/news-releases/general-business-latest-news/general-business-latest-news-list/", "#", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/consumer-technology-latest-news/artificial-intelligence-list/", "/news-releases/consumer-technology-latest-news/blockchain-list/", "/news-releases/consumer-technology-latest-news/cloud-computing-internet-of-things-list/", "/news-releases/consumer-technology-latest-news/computer-electronics-list/", "/news-releases/consumer-technology-latest-news/computer-hardware-list/", "/news-releases/consumer-technology-latest-news/computer-software-list/", "/news-releases/consumer-technology-latest-news/consumer-electronics-list/", "/news-releases/consumer-technology-latest-news/cryptocurrency-list/", "/news-releases/consumer-technology-latest-news/data-analytics-list/", "/news-releases/consumer-technology-latest-news/electronic-commerce-list/", "/news-releases/consumer-technology-latest-news/electronic-gaming-list/", "/news-releases/consumer-technology-latest-news/financial-technology-list/", "/news-releases/consumer-technology-latest-news/mobile-entertainment-list/", "/news-releases/consumer-technology-latest-news/multimedia-internet-list/", "/news-releases/consumer-technology-latest-news/peripherals-list/", "/news-releases/consumer-technology-latest-news/social-media-list/", "/news-releases/consumer-technology-latest-news/science-tech-engineering-math-list/", "/news-releases/consumer-technology-latest-news/supply-chain-logistics-list/", "/news-releases/consumer-technology-latest-news/wireless-communications-list/", "/news-releases/consumer-technology-latest-news/", "/news-releases/consumer-technology-latest-news/consumer-technology-latest-news-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/energy-latest-news/alternative-energies-list/", "/news-releases/energy-latest-news/chemical-list/", "/news-releases/energy-latest-news/electrical-utilities-list/", "/news-releases/energy-latest-news/gas-list/", "/news-releases/energy-latest-news/general-manufacturing-list/", "/news-releases/energy-latest-news/mining-list/", "/news-releases/energy-latest-news/mining-metals-list/", "/news-releases/energy-latest-news/oil-energy-list/", "/news-releases/energy-latest-news/oil-and-gas-discoveries-list/", "/news-releases/energy-latest-news/utilities-list/", "/news-releases/energy-latest-news/water-utilities-list/", "/news-releases/energy-latest-news/", "/news-releases/energy-latest-news/energy-latest-news-list/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/environment-latest-news/conservation-recycling-list/", "/news-releases/environment-latest-news/environmental-issues-list/", "/news-releases/environment-latest-news/environmental-policy-list/", "/news-releases/environment-latest-news/environmental-products-services-list/", "/news-releases/environment-latest-news/green-technology-list/", "/news-releases/environment-latest-news/natural-disasters/", "/news-releases/environment-latest-news/", "/news-releases/environment-latest-news/environment-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/heavy-industry-manufacturing-latest-news/aerospace-defense-list/", "/news-releases/heavy-industry-manufacturing-latest-news/agriculture-list/", "/news-releases/heavy-industry-manufacturing-latest-news/chemical-list/", "/news-releases/heavy-industry-manufacturing-latest-news/construction-building-list/", "/news-releases/heavy-industry-manufacturing-latest-news/general-manufacturing-list/", "/news-releases/heavy-industry-manufacturing-latest-news/hvac-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machinery-list/", "/news-releases/heavy-industry-manufacturing-latest-news/machine-tools-metalworking-and-metallury-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-list/", "/news-releases/heavy-industry-manufacturing-latest-news/mining-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/paper-forest-products-containers-list/", "/news-releases/heavy-industry-manufacturing-latest-news/precious-metals-list/", "/news-releases/heavy-industry-manufacturing-latest-news/textiles-list/", "/news-releases/heavy-industry-manufacturing-latest-news/tobacco-list/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/heavy-industry-manufacturing-latest-news-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "/news-releases/telecommunications-latest-news/carriers-and-services-list/", "/news-releases/telecommunications-latest-news/mobile-entertainment-list/", "/news-releases/telecommunications-latest-news/networks-list/", "/news-releases/telecommunications-latest-news/peripherals-list/", "/news-releases/telecommunications-latest-news/telecommunications-equipment-list/", "/news-releases/telecommunications-latest-news/telecommunications-industry-list/", "/news-releases/telecommunications-latest-news/voip-list/", "/news-releases/telecommunications-latest-news/wireless-communications-list/", "/news-releases/telecommunications-latest-news/", "/news-releases/telecommunications-latest-news/telecommunications-latest-news-list/", "#", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/consumer-products-retail-latest-news/animals-pets-list/", "/news-releases/consumer-products-retail-latest-news/beers-wines-and-spirits-list/", "/news-releases/consumer-products-retail-latest-news/beverages-list/", "/news-releases/consumer-products-retail-latest-news/bridal-services-list/", "/news-releases/consumer-products-retail-latest-news/cannabis-list/", "/news-releases/consumer-products-retail-latest-news/cosmetics-and-personal-care-list/", "/news-releases/consumer-products-retail-latest-news/fashion-list/", "/news-releases/consumer-products-retail-latest-news/food-beverages-list/", "/news-releases/consumer-products-retail-latest-news/furniture-and-furnishings-list/", "/news-releases/consumer-products-retail-latest-news/home-improvements-list/", "/news-releases/consumer-products-retail-latest-news/household-consumer-cosmetics-list/", "/news-releases/consumer-products-retail-latest-news/household-products-list/", "/news-releases/consumer-products-retail-latest-news/jewelry-list/", "/news-releases/consumer-products-retail-latest-news/non-alcoholic-beverages-list/", "/news-releases/consumer-products-retail-latest-news/office-products-list/", "/news-releases/consumer-products-retail-latest-news/organic-food-list/", "/news-releases/consumer-products-retail-latest-news/product-recalls-list/", "/news-releases/consumer-products-retail-latest-news/restaurants-list/", "/news-releases/consumer-products-retail-latest-news/retail-list/", "/news-releases/consumer-products-retail-latest-news/supermarkets-list/", "/news-releases/consumer-products-retail-latest-news/toys-list/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/consumer-products-retail-latest-news/consumer-products-retail-latest-news-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/entertainment-media-latest-news/advertising-list/", "/news-releases/entertainment-media-latest-news/art-list/", "/news-releases/entertainment-media-latest-news/books-list/", "/news-releases/entertainment-media-latest-news/entertainment-list/", "/news-releases/entertainment-media-latest-news/film-and-motion-picture-list/", "/news-releases/entertainment-media-latest-news/magazines-list/", "/news-releases/entertainment-media-latest-news/music-list/", "/news-releases/entertainment-media-latest-news/publishing-information-services-list/", "/news-releases/entertainment-media-latest-news/radio-list/", "/news-releases/entertainment-media-latest-news/television-list/", "/news-releases/entertainment-media-latest-news/", "/news-releases/entertainment-media-latest-news/entertainment-media-latest-news-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/health-latest-news/biometrics-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/clinical-trials-medical-discoveries-list/", "/news-releases/health-latest-news/dentistry-list/", "/news-releases/health-latest-news/fda-approval-list/", "/news-releases/health-latest-news/fitness-wellness-list/", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/health-insurance-list/", "/news-releases/health-latest-news/infection-control-list/", "/news-releases/health-latest-news/international-medical-approval-list/", "/news-releases/health-latest-news/medical-equipment-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/mental-health-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/supplementary-medicine-list/", "/news-releases/health-latest-news/", "/news-releases/health-latest-news/health-latest-news-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/sports-latest-news/general-sports-list/", "/news-releases/sports-latest-news/outdoors-camping-hiking-list/", "/news-releases/sports-latest-news/sporting-events-list/", "/news-releases/sports-latest-news/sports-equipment-accessories-list/", "/news-releases/sports-latest-news/", "/news-releases/sports-latest-news/sports-latest-news-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "/news-releases/travel-latest-news/amusement-parks-and-tourist-attractions-list/", "/news-releases/travel-latest-news/gambling-casinos-list/", "/news-releases/travel-latest-news/hotels-and-resorts-list/", "/news-releases/travel-latest-news/leisure-tourism-list/", "/news-releases/travel-latest-news/outdoors-camping-hiking-list/", "/news-releases/travel-latest-news/passenger-aviation-list/", "/news-releases/travel-latest-news/travel-industry-list/", "/news-releases/travel-latest-news/", "/news-releases/travel-latest-news/travel-latest-news-list/", "#", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "/news-releases/policy-public-interest-latest-news/advocacy-group-opinion-list/", "/news-releases/policy-public-interest-latest-news/animal-welfare-list/", "/news-releases/policy-public-interest-latest-news/congressional-presidential-campaigns-list/", "/news-releases/policy-public-interest-latest-news/corporate-social-responsibility-list/", "/news-releases/policy-public-interest-latest-news/domestic-policy-list/", "/news-releases/policy-public-interest-latest-news/economic-news-trends-analysis-list/", "/news-releases/policy-public-interest-latest-news/education-list/", "/news-releases/policy-public-interest-latest-news/environmental-list/", "/news-releases/policy-public-interest-latest-news/european-government-list/", "/news-releases/policy-public-interest-latest-news/fda-approval-list/", "/news-releases/policy-public-interest-latest-news/federal-and-state-legislation-list/", "/news-releases/policy-public-interest-latest-news/federal-executive-branch-agency-news-list/", "/news-releases/policy-public-interest-latest-news/foreign-policy-international-affairs-list/", "/news-releases/policy-public-interest-latest-news/homeland-security-list/", "/news-releases/policy-public-interest-latest-news/labor-union-news-list/", "/news-releases/policy-public-interest-latest-news/legal-issues-list/", "/news-releases/policy-public-interest-latest-news/natural-disasters-list/", "/news-releases/policy-public-interest-latest-news/not-for-profit-list/", "/news-releases/policy-public-interest-latest-news/patent-law-list/", "/news-releases/policy-public-interest-latest-news/public-safety-list/", "/news-releases/policy-public-interest-latest-news/trade-policy-list/", "/news-releases/policy-public-interest-latest-news/us-state-policy-news-list/", "/news-releases/policy-public-interest-latest-news/", "/news-releases/policy-public-interest-latest-news/policy-public-interest-latest-news-list/", "#", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/news-releases/multicultural-latest-news/native-american-list/", "/news-releases/multicultural-latest-news/african-american-related-news-list/", "/news-releases/multicultural-latest-news/asian-related-news-list/", "/news-releases/multicultural-latest-news/children-related-news-list/", "/news-releases/multicultural-latest-news/diversity-equity-inclusion/", "/news-releases/multicultural-latest-news/hispanic-oriented-news-list/", "/news-releases/multicultural-latest-news/lesbian-gay-bisexual-list/", "/news-releases/multicultural-latest-news/mens-interest-list/", "/news-releases/multicultural-latest-news/people-with-disabilities-list/", "/news-releases/multicultural-latest-news/religion-list/", "/news-releases/multicultural-latest-news/senior-citizens-list/", "/news-releases/multicultural-latest-news/veterans-list/", "/news-releases/multicultural-latest-news/women-related-news-list/", "/news-releases/multicultural-latest-news/", "/news-releases/multicultural-latest-news/multicultural-latest-news-list/", "/ae/ar/news-releases/", "/comunicados-de-prensa/", "/comunicados-para-a-imprensa/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/de/pressemitteilungen/", "/es/comunicados-de-prensa/", "/fr/communiques-de-presse/", "/it/comunicati-stampa/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/fi/lehdistotiedotteet/", "/sv/pressmeddelanden/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/guaranteed-paid-placement/", "/products/all-products/", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "#nav-mobile", "/", "https://portal.prnewswire.com", "/contact-us/", "javascript:void(0)", "/contact-us/", "/contact-us/", "tel:+1-888-776-0942", "javascript:void(0)", "#", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/", "/news-releases/multimedia/", "/news-releases/latest-news-topics/", "/news-releases/automotive-transportation-latest-news/", "/news-releases/business-technology-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/financial-services-latest-news/", "/news-releases/general-business-latest-news/", "/news-releases/consumer-technology-latest-news/", "/news-releases/energy-latest-news/", "/news-releases/environment-latest-news/", "/news-releases/heavy-industry-manufacturing-latest-news/", "/news-releases/telecommunications-latest-news/", "/news-releases/consumer-products-retail-latest-news/", "/news-releases/entertainment-media-latest-news/", "/news-releases/health-latest-news/", "/news-releases/sports-latest-news/", "/news-releases/travel-latest-news/", "/news-releases/multicultural-latest-news/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/products/overview/", "/products/content-distribution/", "/products/communications-cloud/", "/products/ir-compliance/", "/products/all-products/", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/contact-us/#general", "/request-a-demo/", "/contact-us/#editorial", "/contact-us/#partnerships", "/contact-us/#media", "/contact-us/#worldwide", "https://portal.prnewswire.com/", "https://www.prnewswire.com/account/online-membership-form/", "https://portal.prnewswire.com/", "/resources/", "https://www.cision.com/us/blog/", "https://prnmedia.prnewswire.com/", "/rss/", "https://gdpr.cision.com", "https://twitter.com/PRNewswire", "https://www.facebook.com/pages/PR-Newswire/26247320522", "https://www.linkedin.com/company/pr-newswire/", "/news-releases/novavaxs-nuvaxovid-receives-positive-chmp-opinion-for-full-marketing-authorization-for-the-prevention-of-covid-in-the-eu-301835689.html", "/news-releases/novavaxs-nuvaxovid-receives-positive-chmp-opinion-for-full-marketing-authorization-for-the-prevention-of-covid-in-the-eu-301835695.html", "/news-releases/nuvaxovid-von-novavax-erhalt-positive-chmp-stellungnahme-fur-vollstandige-marktzulassung-zur-pravention-von-covid-in-der-eu-301836173.html", "/news-releases/nuvaxovid-de-novavax-recoit-un-avis-positif-du-chmp-pour-lautorisation-dune-autorisation-de-mise-sur-le-marche-complete-pour-la-prevention-de-la-covid-dans-lue-301836711.html", "#", "/news/novavax%2C-inc./", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", null, "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "javascript:void(0)", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=3534653529&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D3454893251%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2021-12-20-European-Commission-Grants-Conditional-Marketing-Authorization-for-Novavax-COVID-19-Vaccine%26a%3Dadults&a=adultos", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2202844626&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2243608504%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-07-05-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Conditionally-Authorized-in-the-European-Union-for-Adolescents-Aged-12-Through-17%26a%3Dadolescents%252C&a=adolescentes", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2627674766&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2102273684%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-09-12-Novavax-Nuvaxovid-TM-COVID-19-Vaccine-Granted-Expanded-Conditional-Marketing-Authorization-in-the-European-Union-for-Use-as-a-Booster-for-Adults-Aged-18-&a=dosis+de+refuerzo+en+adultos", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=4132480547&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D313628848%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3781243-1%2526h%253D2738452371%2526u%253Dhttps%25253A%25252F%25252Fwww.cdc.gov%25252Fvaccines%25252Fcovid-19%25252Fclinical-considerations%25252Fmanaging-anap&a=Centros+para+el+Control+y+la+Prevenci%C3%B3n+de+Enfermedades+(CDC).", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=595147852&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2397580223%26u%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fvaccines%252Fcovid-19%252Fclinical-considerations%252Finterim-considerations-us.html%2523myocarditis-pericarditis%26a%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fvaccines%252Fcovid-19%252Fclinical-considerations%252Finterim-considerations-us.html%2523myocarditis-pericarditis&a=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Fclinical-considerations%2Finterim-considerations-us.html%23myocarditis-pericarditis", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=729331448&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D3497786127%26u%3Dhttp%253A%252F%252Fwww.novavaxmedinfo.com%252F%26a%3Dwww.NovavaxMedInfo.com&a=www.NovavaxMedInfo.com", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2447828334&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D563384075%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3781243-1%2526h%253D1136151556%2526u%253Dhttps%25253A%25252F%25252Fwww.fda.gov%25252Fmedia%25252F159897%25252Fdownload%2526a%253DNovavax%252BCOVID-19%252BVaccine%2525&a=vacuna+contra+el+COVID-19+de+Novavax%2C+la+hoja+informativa+con+adyuvante+para+proveedores+de+atenci%C3%B3n+m%C3%A9dica+que+administran+la+vacuna+(proveedores+de+vacunas)+y+la+informaci%C3%B3n+de+prescripci%C3%B3n+completa+de+la+EUA", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=4223651868&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D1936408935%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3781243-1%2526h%253D170356972%2526u%253Dhttps%25253A%25252F%25252Fnovavax.widen.net%25252Fs%25252Fx5p5tqsdgw%25252Fus-eua-fact-sheet-recipients%2526a%253DFact%2525&a=hoja+informativa+para+beneficiarios+y+cuidadores", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=3673984913&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D1517842101%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3625115-1%2526h%253D371124133%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3440781-1%252526h%25253D467849857%252526u%25253Dhttps%2525253A%2525252F%2525252Fwww.nejm.org%2525252Fdoi%2525252Ffull%2525252F10.1056%2525252FNEJMoa2116185%2525253Fquery%2525253Dfeatured_home%252526a%25253DNew%25252BEngland%25252BJournal%25252Bof%25252BMedicine%2526a%253DNew%252BEngland%252BJournal%252Bof%252BMedicine%26a%3DNew%2BEngland%2BJournal%2Bof%2BMedicine&a=New+England+Journal+of+Medicine", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2530463928&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D3487787302%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial%26a%3DFebruary%2B2022&a=febrero+de+2022", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2732136443&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2988797656%26u%3Dhttps%253A%252F%252Fir.novavax.com%252F2022-10-12-Novavax-Prototype-COVID-19-Vaccine-Data-Support-Homologous-and-Heterologous-Boosting-and-Suggest-Benefit-Against-Variants%26a%3DOctober%2B2022&a=octubre+de+2022", "#financial-modal", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=2467048701&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D1476516171%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3625115-1%2526h%253D372019113%2526u%253Dhttps%25253A%25252F%25252Fc212.net%25252Fc%25252Flink%25252F%25253Ft%25253D0%252526l%25253Den%252526o%25253D3460980-1%252526h%25253D3623927874%252526u%25253Dhttps%2525253A%2525252F%2525252Fc212.net%2525252Fc%2525252Flink%2525252F%2525253Ft%2525253D0%25252526l%2525253Den%25252526o%2525253D3457869-1%25252526h%2525253D982408174%25252526u%2525253Dhttps%252525253A%252525252F%252525252Fc212.net%252525252Fc%252525252Flink%252525252F%252525253Ft%252525253D0%2525252526l%252525253Den%2525252526o%252525253D3440781-1%2525252526h%252525253D3964594936%2525252526u%252525253Dhttps%25252525253A%25252525252F%25252525252Fc212.net%25252525252Fc%25252525252Flink%25252525252F%25252525253Ft%25252525253D0%252525252526l%25252525253Den%252525252526o%25252525253D3395501-1%252525252526h%25252525253D2463599076%252525252526u%25252525253Dhttps%2525252525253A%2525252525252F%2525252525252Fc212.net%2525252525252Fc%2525252525252Flink%2525252525252F%2525252525253Ft%2525252525253D0%25252525252526l%2525252525253Den%25252525252526o%2525252525253D3392093-1%25252525252526h%2525252525253D203886192%25252525252526u%2525252525253Dhttps%252525252525253A%252525252525252F%252525252525252Fc212.net%252525252525252Fc%252525252525252Flink%252525252525252F%252525252525253Ft%252525252525253D0%2525252525252526l%252525252525253Den%2525252525252526o%252525252525253D3387216-1%2525252525252526h%252525252525253D3917401194%2525252525252526u%252525252525253Dhttps%25252525252525253A%25252525252525252F%25252525252525252Fc212.net%25252525252525252Fc%25252525252525252Flink%25252525252525252F%25252525252525253Ft%25252525252525253D0%252525252525252526l%25252525252525253Den%252525252525252526o%25252525252525253D3260461-1%252525252525252526h%25252525252525253D2897486098%252525252525252526u%25252525252525253Dhttp%2525252525252525253A%2525252525252525252F%2525252525252525252Fwww.novavax.com%2525252525252525252F%252525252525252526a%25252525252525253Dwww.novavax.com%2525252525252526a%252525252525253Dwww.novavax.com%25252525252526a%2525252525253Dwww.novavax.com%252525252526a%25252525253Dwww.novavax.com%2525252526a%252525253Dwww.novavax.com%25252526a%2525253Dwww.novavax.com%252526a%25253Dwww.&a=novavax.com", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=895932337&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D318583855%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fnovavax%252Fmycompany%252Fverification%252F%26a%3DLinkedIn&a=LinkedIn", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=1427378382&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2482378409%26u%3Dhttps%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&a=www.sec.gov", "https://www.novavax.com", "/cdn-cgi/l/email-protection#e38a91a38d8c958295829bcd808c8e", "/cdn-cgi/l/email-protection#a9c4cccdc0c8e9c7c6dfc8dfc8d187cac6c4", "https://c212.net/c/link/?t=0&l=es&o=3877129-1&h=3784787682&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3877129-1%26h%3D2238742483%26u%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg%26a%3Dhttps%253A%252F%252Fmma.prnewswire.com%252Fmedia%252F1506866%252FNovavax_High_Res_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F1506866%2FNovavax_High_Res_Logo.jpg", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-announces-grant-of-inducement-awards-pursuant-to-nasdaq-listing-rule-5635c4-301922311.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "novavax-to-participate-in-upcoming-september-conferences-301922087.html", "/news-releases/health-latest-news/health-care-hospitals-list/", "/news-releases/health-latest-news/medical-pharmaceuticals-list/", "/news-releases/health-latest-news/pharmaceuticals-list/", "/news-releases/health-latest-news/biotechnology-list/", "/news-releases/health-latest-news/infection-control-list/", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "https://gdpr.cision.com/PRN-Consumer-Newsletter", "tel:Cision%20Distribution%20888-776-0942", "javascript://Chat", "/contact-us/general-inquiries/", "/request-a-demo/", "/contact-us/editorial-bureaus/", "/contact-us/partnerships/", "/contact-us/media-inquiries/", "/contact-us/worldwide-offices/", "https://twitter.com/PRNewswire", "https://www.facebook.com/PR-Newswire-26247320522/", "https://www.linkedin.com/company/pr-newswire/", "/products/communications-cloud/", "/products/marketing/", "/products/public-relations/", "/products/ir-compliance/", "/products/agency/", "https://www.smallbusinesspr.com/request_information", "/products/all-products/", "https://prnewswire.mediaroom.com/index.php", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "/contact-us/prnewswire-partners/", "/contact-us/become-a-partner/", "https://www.cision.com/careers/", "https://www.cision.com/about/accessibility/", "https://www.prnasia.com/", "https://prnewswire.com.br/", "https://www.newswire.ca/", "/cs/tiskova-zprava/", "/da/pressemeddelelser/", "/fi/lehdistotiedotteet/", "/fr/communiques-de-presse/", "/de/pressemitteilungen/", "/in/news-releases/", "/il/news-releases/", "/it/comunicati-stampa/", "https://prnewswire.com.mx/", "/ae/news-releases/", "https://www.prnewswire.com/ae/ar/news-releases/", "/nl/persberichten/", "/no/pressemeldinger/", "/pl/komunikat-prasowy/", "/pt/comunicados-de-imprensa/", "/ru/press-releases/", "/sk/tlacova-sprava/", "/es/comunicados-de-prensa/", "/sv/pressmeddelanden/", "https://www.prnewswire.co.uk/", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "/contact-us", "/products/overview", "https://prnewswire.mediaroom.com/index.php", "", "/news-releases/", "https://portal.prnewswire.com/Login.aspx", "https://profnet.prnewswire.com/ProfNetHome/What-is-Profnet.aspx", "tel:Cision%20Distribution%20Helpline", "/terms-of-use/", "/privacy-policy/", "/prn-information-security-policy/", "/sitemap/", "/rss/", "/cookie-settings/", "https://www.cision.com/us/?utm_medium=website&utm_source=prnewswire&utm_content=cishomepage&utm_campaign=prnewswire", "javascript://Chat"]}